MedTrace Logo

A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

NCT00298038 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 299

Last updated 2019-09-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Rifaximin

Oral

DRUG

Placebo

Oral

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Lindsey Mathew · Bausch Health Companies

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-19
Primary Completion
2008-08-15
Completion
2008-08-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00298038 on ClinicalTrials.gov